Glucagon-like peptide-1 (GLP-1) receptor agonists

An updated meta-analysis including AMPLITUDE-O supports the cardioprotective effects of glucagon-like peptide-1 receptor agonists regardless of whether they are human- or exendin–4-based.

Click through for more information on this expanded indication

Treatment with efpeglenatide significantly improves glycemic control and results in weight loss for medication-naïve people with type 2 diabetes, report the AMPLITUDE-M researchers.

Findings from the DISCOVER study indicate that global use of SGLT2 inhibitors and GLP-1 receptor agonists has increased over time among people with type 2 diabetes, but remains suboptimal.

People with type 2 diabetes who lose weight while taking semaglutide have a parallel improvement in their health-related quality of life, particularly that related to physical exertion, report the STEP 2 investigators,

Further analyses from STEP 2 show improvements in multiple cardiometabolic risk markers with semaglutide versus placebo, and potentially greater weight loss in women than men.

Taking semaglutide 2.4 mg can reduce the likelihood of people with overweight or obesity developing type 2 diabetes, shows further analysis of STEP 1.

Findings from the GRADE study, a head-to-head comparison of four commonly used diabetes drugs given together with metformin, suggest that liraglutide and insulin may result in better glycemic control than glimepiride and sitagliptin among people with type 2 diabetes.

Efpeglenatide provides significant cardiovascular and renal protection in people with type 2 diabetes at high risk for cardiorenal events, show the findings of the AMPLITUDE-O trial.

People with type 2 diabetes taking a weekly semaglutide dose of 2.0 mg experience significantly greater reductions in glycated hemoglobin and bodyweight than those taking the standard 1.0 mg dose, show phase 3 trial results.

People with type 2 diabetes on metformin monotherapy have greater glycemic control improvement and weight reduction with tirzepatide than semaglutide, report the SURPASS-2 investigators.

Long-term dulaglutide use may reduce the incidence of moderate or severe erectile dysfunction in men with type 2 diabetes, particularly those with underlying cardiovascular disease, shows an exploratory analysis of REWIND data.

Click through to read more on this announcement

Giving semaglutide to people undergoing minimally invasive endoscopic sleeve gastroplasty may bring weight loss closer to that induced by bariatric surgery, shows research.

Phase 1 trial results published in The Lancet suggest that combination treatment with the long-acting amylin analog cagrilintide plus high-dose semaglutide is well tolerated and may be a feasible treatment option for obesity.

Combining a GLP-1 receptor agonist or SGLT2 inhibitor with basal insulin allows people with type 2 diabetes on a basal–bolus regimen to drop the prandial insulin, shows the pragmatic BEYOND trial.

Combining metformin with a sulfonylurea produces poorer non-glycemic outcomes than combining it with other second-line agents, show results from the global DISCOVER program.

A Mendelian analysis supports a causal effect of hyperglycemia on stroke risk, and the researchers also pinpoint the medications most likely to reduce this risk.

SGLT2 inhibitor treatment could lower the risk for incident and recurrent kidney stones in people with type 2 diabetes, suggest Danish study results.

People with obesity continue to lose weight if they remain on semaglutide 2.4 mg after an initial 20 weeks of treatment, but gradually regain it if they switch to placebo, show the STEP 4 findings.